FuturHealth

What FuturHealth does

FuturHealth is a San Diego-based, privately held telehealth platform founded in 2023 that delivers membership-based, personalized weight management programs combining prescription GLP-1 medications, dietitian-designed nutrition plans, and ongoing virtual clinician support. The platform serves individual consumers seeking FDA-approved and compounded GLP-1 therapies without insurance, offering oral options (Foundayo/orforglipron, Wegovy pill) and injectables (Zepbound, Ozempic, Mounjaro, Wegovy injection, compounded semaglutide) prescribed through a network of licensed providers. Underlying technology includes a mobile app (iOS and Android) for intake, tracking, and clinician communication, integrated with Apple Fitness+, third-party pharmacy fulfillment (Alto Pharmacy), Affirm payment financing, and HITRUST i1-certified data infrastructure that has facilitated over 6 billion online interactions to date.

The company operates a direct-to-consumer subscription model priced at $129-$198/month for membership plus $229-$1,299/month for medication depending on compound versus branded tier, with branded medication pricing reaching approximately $1,428/month. GTM motion combines a website acquisition funnel (funnel.fh.co) with referral-driven traffic, supported by extensive PR coverage in 2025. FuturHealth has served 400,000+ cumulative members, scaled its provider network from 350 to 6,000 across 48 states, and reported 980% year-over-year growth in active patients, positioning it among the higher-velocity players in the cash-pay GLP-1 telehealth category.

Revenue is generated from recurring monthly subscriptions and medication fulfillment margins, supplemented by Affirm transaction fees on financed purchases. Key risks include supplier concentration on Eli Lilly and Novo Nordisk, regulatory exposure to compounding pharmacy oversight and telehealth licensing across states, high category churn typical of weight-loss programs, and the absence of disclosed funding which makes the cash position supporting this growth trajectory unverified.

Name

FuturHealth

Legal name

FuturHealth, Inc.

Website

https://futurhealth.com

Company type

Private

Founded year

2023

Operating status

Operating

Headcount range

11–50 employees

Short description

FuturHealth is a San Diego-based telehealth platform offering membership-based weight management programs combining GLP-1 medications, personalized nutrition, and virtual clinician support. It serves 400,000+ individual consumers across 48 US states through a 6,000-provider network.

Ownership category

akta.pro rank

Product category

Telehealth Weight Management

NAICS

Diet and Weight Reducing Centers (812191)

SIC

Services-Misc Health & Allied Services, Nec (8090)

akta.pro primary industry

Membership/Subscription Concierge Virtual Care (HLALAAAH)

akta.pro secondary industries

Chronic Condition Medication Programs (e.g., diabetes, hypertension) with Integrated Prescribing (HLALAIAH), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Telehealth weight management
• GLP-1 medication access
• Personalized nutrition plans
• Prescription weight loss
• Virtual clinician consultations

Headquarters

HQ city

San Diego

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Supply Chain, Personnel, Operations, Marketing or Sales, Technology or R&D

Revenue model

1. Monthly Membership Subscription: The primary revenue stream comes from monthly membership subscriptions that provide access to the digital platform, clinician guidance, personalized nutrition plans, and Apple Fitness+ access. Pricing varies by medication type and program tier, starting at $129/month for base membership.
2. Medication Fulfillment: Revenue from medication fulfillment through third-party pharmacies. Options include compounded GLP-1 medications (~$229/month) and branded medications like Ozempic or Wegovy (~$1,299/month), with prices varying based on medication type and dosage.
3. Affirm Financing: Partnership with Affirm provides flexible payment options including 0% APR plans for customers to finance GLP-1 medications and wellness solutions over time, addressing the high cost of medications (which can exceed $1,000/month).

Pricing tiers

Go-to-market motion2 records

Distribution channels4 records

Marketing channels5 records

Core offering

FuturHealth operates a direct-to-consumer telehealth platform that provides access to GLP-1 weight loss medications (oral pills such as Foundayo™ and Wegovy®, plus injectables such as Ozempic®, Zepbound®, Mounjaro®, and compounded semaglutide) combined with personalized nutrition plans, virtual clinician support, and a mobile tracking app. Members enroll online, complete a medical intake, are evaluated by a licensed provider, and receive ongoing care and home-delivered medication through a monthly membership subscription starting at $198/month, with no insurance required.

Product overview

FuturHealth is a telehealth weight-loss platform offering a comprehensive, membership-activated program that combines FDA-approved GLP-1 medications (including oral pills like Foundayo™ and Wegovy®, plus injectable options like Zepbound®, Ozempic®, and Mounjaro®) with personalized nutrition plans, virtual clinician support, and wellness integrations. The platform operates on a subscription model ($198/month for GLP-1 accommodating program) and provides access through a network of 350+ providers across 48 states. The core offering includes medication prescriptions, a digital app for tracking and support, Apple Fitness+ integration, and customized GLP-1 meal programs, all designed to work together as an integrated weight management solution.

Differentiator

Problem solved

Functional benefit

Products and services

• Foundayo™ Pill (Orforglipron)
• Wegovy® Oral Pill
• Wegovy® Semaglutide Injection
• Zepbound® Tirzepatide Injection
• Ozempic® Semaglutide Injection
• Mounjaro®
• Compounded Semaglutide
• Personalized Nutrition & Meal Plans

Quantifiable outcome

• Patients lose 58.5% more weight with FuturHealth's full program compared to medicine alone
• +4 more outcomes

Named customers1 record

Segments2 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Integration3 records

Feature3 records

Partnerships

Six partnerships are on record, tiered core and major.

• Eli LillycoreTechnology or Integration · 29 October 2025FuturHealth became one of the first clinically guided health platforms to offer orforglipron (brand name Foundayo), Eli Lilly's oral GLP-1 receptor agonist, providing eligible members with once-daily pill option delivered to homes.
• Apple Fitness+coreStrategic or Co-development Partner · 11 August 2025FuturHealth offers enrolled members complimentary access to Apple Fitness+ at no additional cost as part of its holistic wellness approach. The integration provides access to thousands of workouts and meditations across 12 workout types on iPhone, iPad, and Apple TV.
• Alto PharmacymajorChannel Partner/ Reseller/ Distributor · 31 July 2025Alto Pharmacy provides next-day home delivery of FDA-approved GLP-1 medications including Wegovy through Novo Nordisk's cash-pay program.
• Novo NordiskcoreTechnology or Integration · 31 July 2025FuturHealth provides access to FDA-approved GLP-1 medications including Wegovy through Novo Nordisk's cash-pay program at prices starting at $299 for the first month.
• ValisurecoreTechnology or Integration · 26 February 2025Strategic partnership with independent laboratory Valisure to provide quality testing and certification for compounded GLP-1 medications, addressing concerns about purity, carcinogens, and dosage accuracy in the weight management sector.
• InCSD (Informed Consent and Scientific Data)majorStrategic or Co-development Partner · 26 February 2025InCSD partnered with FuturHealth on a retrospective study of 33,740 patients demonstrating enhanced weight loss outcomes when combining the program with GLP-1 treatments.

Scale indicators12 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Ro: Ro is a leading direct-to-consumer telehealth platform offering weight-loss programs using GLP-1 medications combined with clinician support. It is a direct competitor to FuturHealth with an overlapping patient base and similar cash-pay subscription model.
• Hims & Hers Health: Hims & Hers Health is a publicly-traded telehealth company that has aggressively expanded into weight loss with GLP-1 medications, including compounded and branded options. It competes with FuturHealth for cash-pay consumers seeking telehealth weight management.
• Henry Meds: Henry Meds is a direct-to-consumer telehealth platform specializing in weight loss using compounded and branded GLP-1 medications. It targets a very similar cash-pay, online-only patient population as FuturHealth.
• LifeMD: LifeMD is a publicly-traded telehealth company with a direct-to-consumer weight management program using GLP-1 medications. It is a direct competitor to FuturHealth in the cash-pay, subscription-based virtual care model.
• Calibrate: Calibrate is a metabolic-health focused telehealth program combining GLP-1 medication with coaching and lifestyle intervention. It is a direct competitor to FuturHealth in the integrated medication-plus-lifestyle model.
• Found: Found is a direct-to-consumer telehealth weight management platform offering personalized care with clinicians and access to multiple medication options. It targets the same cash-pay consumer as FuturHealth.

Emerging players

• Eden: Eden is a direct-to-consumer telehealth platform offering GLP-1 weight loss programs with clinicians and ongoing support. It is an emerging competitor with similar positioning to FuturHealth, though at a smaller scale.
• Sesame: Sesame is a direct-to-consumer telehealth marketplace that has expanded into weight management with clinician visits and prescriptions. It overlaps with FuturHealth in offering cash-pay virtual care but uses a marketplace model.

Broad incumbents

• Noom: Noom is a large-scale digital health and weight management platform with coaching, psychology-based programs, and a growing medication offering. It competes with FuturHealth for weight-loss consumers, though historically with a coaching-led model rather than prescribing.
• WeightWatchers (WW): WeightWatchers, including its Sequence / WW Clinic GLP-1 program, is a broad incumbent in weight management that has expanded into telehealth-prescribed GLP-1 medications. It serves overlapping consumers with a more established brand and behavioral-program legacy.

Market position

Strengths4 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Facebookfacebook.com/yourfuturhealth
• Instagraminstagram.com/yourfuturhealth
• TikToktiktok.com/@yourfuturhealth
• LinkedInlinkedin.com/company/futurhealth

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles6 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about FuturHealth